N
NextCell Pharma AB
STO:NXTCL
NextCell Pharma AB
STO:NXTCL
Price:
1.102
SEK
-4.01%
Market Closed
Market Cap:
kr122.8m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Popular Picks
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NextCell Pharma AB
Net Issuance of Debt
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
NextCell Pharma AB
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NextCell Pharma AB
STO:NXTCL
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Net Issuance of Debt
-kr6.8m
|
CAGR 3-Years
9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Net Issuance of Debt
-kr6.7m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Net Issuance of Debt
-kr424m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-94%
|
CAGR 10-Years
N/A
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Net Issuance of Debt
-kr5.1B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
BioArctic AB
STO:BIOA B
|
Net Issuance of Debt
kr890k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
No Stocks Found
NextCell Pharma AB
Glance View
NextCell Pharma AB engages in the development of stem cell products. The company is headquartered in Huddinge, Stockholm. The company went IPO on 2017-07-13. The firm is focusing on research and development of stem cell therapies and is also running a tissue establishment and biobank, classified as healthcare provider. NextCell's business concept is to develop and commercialize mesenchymal stem cell products based on the Company's proprietary selection algorithm, primarily for the treatment of autoimmune diabetes, as well as other types of autoimmune diseases.
NXTCL
Intrinsic Value
1.178
SEK
Undervaluation 6%
N
